Allergy Therapeutics (GB:AGY) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Allergy Therapeutics has announced promising interim results from its Phase I/IIa trial of VLP Peanut, a potential new treatment for peanut allergies. The data shows a significant reduction in skin sensitivity among patients and suggests the treatment can effectively boost immune response while reducing allergic reactions. This progress marks a significant step forward in developing a novel therapy for peanut allergy, with plans to continue dose escalation in future trials.
For further insights into GB:AGY stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue